Topical Peptide Research: Barrier Limits, Peptide Classes and Formulation Arithmetic

Nothing else about a topical peptide counts until it has got through the stratum corneum, and that one limit, around 500 Da for passive diffusion across intact skin, is why cosmetic research peptides are almost always tri-, tetra- or pentapeptides rather than the longer chains used in injectable work. Topical peptides come as water-based serums, emulsified creams and alcohol-based scalp solutions, and the vehicle materially alters how much peptide arrives at the viable epidermis. This guide covers the barrier itself, the four classes used in cosmetic research, how a loading percentage becomes a concentration, and where the published evidence stops. It describes laboratory and cosmetic research preparations.

The barrier and its 500-dalton ceiling

Between 10 and 20 µm thick, the stratum corneum consists of anucleate corneocytes set in a lamellar lipid matrix of ceramides, cholesterol and free fatty acids. Passive permeation happens chiefly through that lipid phase, which suits small, mildly lipophilic molecules. The much-quoted "500 Dalton rule", derived from analysis of topically active drugs and contact allergens, states that anything heavier than about 500 Da seldom crosses intact skin in useful quantities.

Peptides are water-loving and frequently charged, which puts them at a double disadvantage. Three strategies get round it:

• Keep the molecule small. At 403.93 Da, the GHK-Cu tripeptide-copper complex sits well below the limit.
• Attach a lipid tail. Palmitoylation fixes a 16-carbon fatty acid to the N-terminus, lifting the partition coefficient so the peptide dissolves into the lipid lamellae. Palmitoyl pentapeptide-4 (Matrixyl, 802.05 Da) is over 500 Da yet permeates measurably thanks to that tail.
• Alter the vehicle. Ethanol, propylene glycol, glycerol and some surfactants loosen the lipid matrix, while occlusion beneath an emulsion hydrates corneocytes and opens up the intercellular route.

The four cosmetic research classes

Observe that both neurotransmitter-inhibitor peptides exceed 500 Da and have no lipid tail. Published studies show only modest permeation for them, and this is the most disputed corner of the cosmetic peptide literature: an in-vitro SNARE-competition finding demonstrates a mechanism in a dish, not delivery through intact skin to a neuromuscular junction.

Where the evidence actually reaches

GHK-Cu carries the longest record: Loren Pickart's group isolated it from human plasma in the early 1970s, and later work reported effects on collagen, glycosaminoglycan and decorin synthesis in fibroblast culture and in wound models, along with several small split-face human studies on skin appearance. The background sits in what is GHK-Cu. Matrixyl's evidence comes largely from manufacturer-run fibroblast work plus a handful of controlled human studies. For Argireline the record is dominated by in-vitro mechanism studies and vendor-sponsored clinical trials with small cohorts. In each case the honest verb is "reported in" rather than "shown to", and none of these materials treats any condition.

Turning percentages into concentrations

Cosmetic labels speak in percentages while research protocols need molarity, and converting between them is straightforward once the units are fixed.

1. From percent to mg/mL: 1% w/v means 1 g per 100 mL, so 10 mg/mL. A 0.05% w/v formulation is therefore 0.5 mg/mL, equal to 500 µg/mL or 500 ppm.
2. Making a 30 mL serum at 0.05% GHK-Cu: 30 mL × 0.5 mg/mL requires 15 mg of peptide, so a 50 mg research vial yields three bottles with material left over.
3. From percent to molarity: 0.5 mg/mL equals 0.5 g/L, which divided by the molecular weight of 403.93 g/mol gives 1.24 mM. Since fibroblast studies usually operate between 1 and 100 µM, a 0.05% topical serum is something like 10 to 1,000 times more concentrated than culture medium, before any barrier losses.
4. Interpreting a "10%" label: a serum sold as Argireline 10% nearly always contains 10% of a supplied concentrate, and that concentrate itself is typically a 5% peptide solution. Real acetyl hexapeptide-8 content therefore lands around 0.5% w/v rather than 10%. Where the figure matters to your design, request peptide content in mg/mL.

That final point is the commonest misreading in this category and belongs in any protocol comparing products.

Choosing the vehicle

• Water-based serums such as the GHK-Cu face serum and Matrixyl serum hold hydrophilic peptides in their preferred phase, dry fast and offer the briefest contact. They suit small, water-soluble peptides.
• Emulsified creams such as the GHK-Cu cream contribute occlusion, hydrating corneocytes and lengthening contact. In exchange the matrix grows more complex, giving the peptide more chance to partition into the oil phase and never arrive at the skin.
• Alcohol- or glycol-based solutions such as the GHK-Cu hair and scalp solution spread across hair-bearing skin and use the follicular route, which avoids the stratum corneum altogether and weighs unusually heavily in hair research.
• Combination products such as the GHK-Cu + SNAP-8 serum put a permeating carrier peptide beside a larger one; read any result as the formulation's rather than either peptide's.

Formulation chemistry that destroys peptides

• pH. GHK-Cu's copper coordination depends on pH and is most stable near neutral, so strongly acidic vehicles, a pH 3.5 vitamin C serum for instance, strip the copper and change the molecule.
• Chelators. EDTA, a standard cosmetic preservative booster, chelates copper and has no place in a copper-peptide formulation.
• Powerful oxidising and reducing agents. Methionine, cysteine and tryptophan oxidise easily, so layering copper peptides with high-percentage ascorbic acid or with retinoids is a chemical incompatibility rather than a routine.
• Preservation. Any water-containing formulation needs a preservative system. An unpreserved homemade serum lasts only days refrigerated, and microbial growth typically ruins it long before the peptide degrades.

Frequent errors

• Treating a concentrate percentage as a peptide percentage; the two differ by roughly tenfold.
• Assuming a big peptide permeates because a small one does. The 500 Da threshold is a genuine discontinuity, and a lipid tail, not optimistic formulating, is what carries a molecule past it.
• Putting a copper peptide into an EDTA-containing or low-pH vehicle.
• Quoting fibroblast culture data as skin outcomes. Concentration in a dish and concentration in viable epidermis after barrier losses are two different quantities.

The complete range is in the topical peptide creams and serums collection.